Although most clinical studies of blocking PD-1 and CTLA-4 with humanized monoclonal antibodies are directed at solid tumors and lymphoma, PD-1 and CTLA-4 also play a role in leukemia, GVL and GVHD (131). Here, CTLA4 is linked to leukemia.